Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 8c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
May 1, 2019 7:30 AM EDTSuccessfully Completed $70 Million Financing
On Track for Multiple Data Readouts for Clinical-Stage Programs in 2019 and 2020
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2019 and provided an update on recent accomplishments and upcoming events.
Our first quarter accomplishments mark important progress against our strategic priorities for 2019, said Nancy... More
